Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Itacitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 known ✓ | P23458 | 10/20 | 1.00 |
| ▸ | JAK2 | O60674 | 18/20 | 1.00 |
| ▸ | MERTK | Q12866 | 2/20 | 1.00 |
| ▸ | TYK2 | P29597 | 1/20 | 1.00 |
| ▸ | AXL | P30530 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 1/20 | 1.00 |
| ▸ | TYRO3 | Q06418 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Itacitinib SCHEMBL29377548 | 1.00 | JAK2 (1.00) | JAK2JAK1MERTKTYK2AXL | |
| Itacitinib SCHEMBL29456952 | 1.00 | JAK2 (1.00) | JAK2JAK1MERTKTYK2AXL | |
| Itacitinib SCHEMBL29360482 | 1.00 | JAK2 (1.00) | JAK2JAK1MERTKTYK2AXL | |
| Itacitinib SCHEMBL29395727 | 0.96 | JAK2 (0.92) | JAK2JAK1MERTKTYK2AXL | |
| Itacitinib SCHEMBL29395309 | 0.96 | JAK2 (0.92) | JAK2JAK1MERTKTYK2AXL | |
| Itacitinib SCHEMBL29379939 | 0.96 | JAK2 (0.92) | JAK2JAK1MERTKTYK2AXL | |
| Itacitinib SCHEMBL2392474 | 0.96 | JAK2 (0.92) | JAK2JAK1MERTKTYK2AXL | |
| Itacitinib SCHEMBL30986034 | 0.94 | JAK2 (0.88) | JAK2JAK1MERTKTYK2AXL | |
| Itacitinib SCHEMBL2392537 | 0.94 | JAK2 (0.88) | JAK2JAK1MERTKTYK2AXL | |
| SCHEMBL24327904 | 0.93 | JAK2 (0.86) | JAK2JAK1MERTKTYK2AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 572 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127724-A1 | SUSTAINED RELEASE DOSAGE FORMS FOR A JAK1 INHIBITOR | INCYTE CORPORATION | 2025-04-24 | — | — | US | claimed |
| EP-4501409-A2 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | Incyte Holdings Corporation (US) | 2025-02-05 | — | — | EP | claimed |
| US-20240390378-A1 | USE OF JAK1 INHIBITORS FOR THE TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOSUS AND LICHEN PLANUS (LP) | INCYTE CORPORATION | 2024-11-28 | — | — | US | claimed |
| US-12151026-B2 | Sustained release dosage forms for a JAK1 inhibitor | INCYTE CORPORATION (US) | 2024-11-26 | — | — | US | claimed |
| US-11992490-B2 | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) | INCYTE CORPORATION (US) | 2024-05-28 | — | — | US | claimed |
| US-20240156818-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS | INCYTE CORPORATION | 2024-05-16 | — | — | US | claimed |
| EP-3773593-B1 | TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORS | INCYTE CORP (US) | 2024-05-15 | — | — | EP | claimed |
| EP-4036088-B1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORP (US) | 2024-04-03 | — | — | EP | claimed |
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | INCYTE CORPORATION | 2024-03-21 | — | — | US | claimed |
| CN-117693339-A | JAK1 pathway inhibitors for the treatment of prurigo nodularis | 因赛特公司 | 2024-03-12 | — | — | CN | claimed |
| WO-2015184305-A1 | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 | INCYTE CORPORATION (US) | 2015-12-03 | — | — | WO | claimed |
| WO-2015157257-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR | INCYTE CORPORATION (US) | 2015-10-15 | — | — | WO | claimed |
| WO-2015131031-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION (US) | 2015-09-03 | — | — | WO | claimed |
| US-20150246046-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INCYTE CORPORATION | 2015-09-03 | — | — | US | claimed |
| US-20150065484-A1 | SUSTAINED RELEASE DOSAGE FORMS FOR A JAK1 INHIBITOR | INCYTE CORPORATION (US) | 2015-03-05 | — | — | US | claimed |
| US-20150065447-A1 | SURVIVAL BENEFIT IN PATIENTS WITH SOLID TUMORS WITH ELEVATED C-REACTIVE PROTEIN LEVELS | INCYTE CORPORATION (US) | 2015-03-05 | — | — | US | claimed |
| WO-2015026818-A1 | SURVIVAL BENEFIT IN PATIENTS WITH SOLID TUMORS WITH ELEVATED C-REACTIVE PROTEIN LEVELS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | WO | claimed |
| US-20140275031-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | claimed |
| US-8765734-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE CORPORATION (US) | 2014-07-01 | — | — | US | claimed |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2011-09-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065484-A1 | SUSTAINED RELEASE DOSAGE FORMS FOR A JAK1 INHIBITOR | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885MERTK 871/4885 |
| US-20150065447-A1 | SURVIVAL BENEFIT IN PATIENTS WITH SOLID TUMORS WITH ELEVATED C-REACTIVE PROTEIN LEVELS | JAK2, STAT3, IL6 | JAK1 4/4885JAK2 1/4885MERTK 172/4885 |
| US-20240390378-A1 | USE OF JAK1 INHIBITORS FOR THE TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOSUS AND LICHEN PLANUS (LP) | JAK1, JAK3, JAK2 | JAK1 1/4885JAK2 3/4885MERTK 1062/4885 |
| US-20150246046-A1 | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885MERTK 447/4885 |
| US-20250127724-A1 | SUSTAINED RELEASE DOSAGE FORMS FOR A JAK1 INHIBITOR | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885MERTK 871/4885 |
| US-20240156818-A1 | JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS | JAK1, IRAK1, STAT3 | JAK1 1/4885JAK2 8/4885MERTK 61/4885 |
| US-20240091234-A1 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | JAK2, JAK1, BTK | JAK1 2/4885JAK2 1/4885MERTK 452/4885 |
| US-20140275031-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885MERTK 844/4885 |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885MERTK 844/4885 |
| US-12151026-B2 | Sustained release dosage forms for a JAK1 inhibitor | JAK1, JAK2, JAK3 | JAK1 1/4885JAK2 2/4885MERTK 871/4885 |
| US-11992490-B2 | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) | JAK1, JAK3, JAK2 | JAK1 1/4885JAK2 3/4885MERTK 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.